- Expansion of syndicate permits broadening of platforms, growth of pipeline and extension of runway
- Lead platform centered on engineered tRNAs for human illnesses attributable to untimely termination codons (PTCs)
CAMBRIDGE, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) — hC Bioscience, Inc., an organization creating first-in-class tRNA-based therapeutics focusing on protein dysfunction in genetically outlined illnesses, immediately introduced an extension of $16 million to its Series A funding spherical, bringing the whole raised to $40 million. Taiho Ventures and Panacea Venture joined present buyers, ARCH Venture Partners, Takeda Ventures and 8VC.
hC Bioscience is creating engineered tRNAs with the facility to overcome disease-causing points within the genetic code as proteins are made. hC Bio’s improvements in precision protein enhancing therapies goal genetically-defined illnesses together with most cancers. A single tRNA remedy has the potential to deal with many illnesses, regardless of the gene or location of the mutation.
“We are thrilled to announce our Series A extension of $16 million and welcome Seiji Miyahara, Taiho Ventures, and Benjamin Chen, Panacea Venture, to our board of directors,” stated Leslie Williams, co-founder, director and chief govt officer of hC Bioscience. “The additional support will allow us to expand our pipeline more rapidly and extend our runway,” Williams stated. “We are excited to advance our lead drug candidates in cancer and genetic disease by delivering tRNA both locally and systemically.”
Dr. Steven Gillis, chairman of the board, acknowledged, “This follow-on financing in challenging markets further validates the potential of hC Bio’s approach to advance tRNA based treatments. It further underscores investor confidence in the hC Bioscience team to continue to make progress toward bringing tRNA based therapeutics to the clinic.”
About hC Bioscience, Inc.
hC Bioscience is devoted to enhancing the lives of sufferers with the event of first-in-class tRNA-based therapeutics focusing on protein dysfunction. hC Bioscience’s progressive strategy to precision protein enhancing has the potential to deal with genetically outlined situations which account for 10-15% of all human illness. The lead platform in growth is directed at restoring protein perform in illnesses attributable to nonsense mutations or untimely termination codons (PTCs). A single tRNA remedy has the potential to deal with many illnesses, regardless of the gene or location of the mutation.
Media Contact:
Andrew Mielach
(646) 876-5868
[email protected]
